Background: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized. Objective: The aim of this study was to report the reasons for requesting neurological consultations by internists and intensivists in a COVID-19-dedicated hospital. Methods: This retrospective study was carried out at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, a 900-bed COVID-19 dedicated center (including 300 intensive care unit beds). COVID-19 diagnosis was confirmed by SARS-CoV-2-RT-PCR in nasal swabs. All inpatient neurology consultations between March 23rd and May 23rd, 2020 were analyzed. Neurologists performed the neurological exam, assessed all available data to diagnose the neurological condition, and requested additional tests deemed necessary. Difficult diagnoses were established in consensus meetings. After diagnosis, neurologists were involved in the treatment. Results: Neurological consultations were requested for 89 out of 1,208 (7.4%) inpatient COVID admissions during that period. Main neurological diagnoses included: encephalopathy (44.4%), stroke (16.7%), previous neurological diseases (9.0%), seizures (9.0%), neuromuscular disorders (5.6%), other acute brain lesions (3.4%), and other mild nonspecific symptoms (11.2%). Conclusions: Most neurological consultations in a COVID-19-dedicated hospital were requested for severe conditions that could have an impact on the outcome. First-line doctors should be able to recognize neurological symptoms; neurologists are important members of the medical team in COVID-19 hospital care.
Objective: To describe the clinical, neurological, neuroimaging and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center. Methods: We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results: Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate and severe encephalopathy groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy patients, but did not correlate with the severity of encephalopathy. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination. Four had suffered an acute stroke. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood cell count and all were negative for oligoclonal bands. In our case series the severity of encephalopathy correlated with higher probability of death during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy, from absent (0) to mild (1), moderate (2) or severe (3), p<0.001). Conclusion: In our consecutive series with 43 encephalopathy cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation as the cause of encephalopathy.
Somatic neurological complications are an underexplored component of post-acute sequelae of SARS-CoV-2 infection. We evaluated long-term somatic neurological symptoms, examination findings, and suspected diagnoses among adults hospitalized for COVID-19. A total of 708 survivors were assessed 6–11 months after discharge using a structured three-step neurological evaluation based on the World Health Organization Protocol for Epidemiologic Studies of Neurologic Disorders : an adapted symptom questionnaire, a brief standardized neurological examination, and a full neurological consult. Muscle weakness, gait impairment, and paresthesias remained the most frequent symptoms at follow-up. Longer hospital stay predicted all three symptoms, and diabetes was associated with both gait impairment and paresthesias. Common examination findings included monoparesis, hemiparesis, and gradient-pattern sensory loss. Clinically suspected diagnoses included neuromuscular disease in 26%, cerebrovascular disease in 10%, and epilepsy in only 2.7% of cases. Logistic regression linked neuromuscular disease to paresthesias and tandem-walk failure, cerebrovascular disease to facial paralysis, and epilepsy to loss-of-contact episodes. A simplified screening model derived through best-subsets selection identified five informative items from the WHO protocol: paresthesias, facial paralysis, tandem walk, index–nose test, and loss-of-contact episodes. These findings indicate that somatic neurological abnormalities remain frequent months after severe COVID-19 and that a brief bedside subset may support efficient post-COVID neurological triage.
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.
Background: Alzheimer's disease (AD) has evolved from a syndromic diagnosis to a biologically defined entity supported by cerebrospinal fluid (CSF) biomarkers. The Alzheimer's Association 2024 (AA-2024) criteria are expected to expand biological AD classification compared with the 2018 NIA–AA AT(N) framework. Objective: To compare biological AD classification using the AT(N) 2018 framework and the AA-2024 criteria in a real-world cohort. Methods: We conducted a retrospective study including 146 consecutive patients evaluated for cognitive impairment in a tertiary neurology center who underwent CSF biomarker testing (Aβ 42 , Aβ 40 , Aβ 42 /Aβ 40 ratio, phosphorylated tau, and total tau). Each patient was classified according to AT(N) 2018 and AA-2024 criteria. Diagnostic distributions, reclassification patterns, and agreement (Cohen's κ) were analyzed. Group comparisons used Wilcoxon rank-sum and Fisher's exact tests. Results: Under AT(N) 2018, 40/146 (27.4%) patients met biological AD criteria, whereas AA-2024 classified 72/146 (49.3%) as AD. Reclassification occurred exclusively from non-AD to AD (32 patients, 21.9%), with no reverse reclassification. Agreement was moderate (κ = 0.57). Concordant AD cases (AD+/AD+) showed lower Aβ 42 /Aβ 40 ratios and higher total and phosphorylated tau levels than reclassified cases (AD−/AD+) (all p < 0.001), as well as higher neurodegeneration marker positivity (70% versus 25%; p < 0.001). Final clinical AD diagnosis was assigned to 98% of concordant cases versus 38% of reclassified cases (p < 0.001). Conclusions: AA-2024 increases biological AD classification by identifying amyloid-positive individuals with lower tau burden and clinical heterogeneity, underscoring the need to integrate biomarker-based definitions with clinical and longitudinal assessment.